Journal
VACCINE
Volume 27, Issue 18, Pages 2426-2436Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.02.073
Keywords
Francisella tularensis; Tularemia vaccine; LVS
Categories
Funding
- NIH Cooperative Agreement [U54 AI57168]
Ask authors/readers for more resources
Francisella tularensis, the etiologic agent of tularemia, can cause severe and fatal infection after inhalation of as few as10-100 CFU. F.tularensis is a potential bioterrorism agent and, therefore, a priority for countermeasure development. Vaccination with the live vaccine strain (LVS), developed from a Type B strain, confers partial protection against aerosal exposure to the more virulent Type A strains and provides proof of principle that a live attenuated vaccine strain may be efficacious. However LVS suffers from several notable drawbacks that have prevented its licensure and widespread use. To address the specific deficiencies that render LVS a sub-optimal tularemia vaccine, we engineered F tularensis LVS strains with targeted deletions in the guaA or guaB genes that encode critical enzymes in the guanine nucleotide biosynthetic pathway. F.tularensis LVS Delta guaA and LVS Delta guaB Mutants were guanine auxotrophs and were highly attenuated in a mouse model of infection. While the mutants failed to replicate in macrophages, a robust proinflammatory cytokine response, equivalent to that of the parental LVS, was elicited. Mice vaccinated with a single dose of the F tularensis LVS Delta guaA or LVS Delta guaB mutant were fully protected against Subsequent lethal challenge with the LVS parental strain. These findings suggest the specific deletion of these target genes could generate a safe and efficacious live attenuated vaccine. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available